NEW DELHI: In a significant move aimed at strengthening drug regulation and enhancing patient safety, the Union Ministry of Health and Family Welfare has amended existing drug rules to prohibit the sale of syrups, including cough syrups, without a valid prescription from a registered medical practitioner.
The amendment has been notified through the Drugs (Fifth Amendment) Rules, 2026, published in the official gazette, and has come into effect immediately.
According to official sources, the decision seeks to bring syrup-based formulations, particularly cough syrups and other liquid oral medicines, under stricter regulatory oversight amid growing concerns over drug quality and patient safety.
As per the notification issued by the Ministry of Health and Family Welfare, the word “syrups” has been removed from Item 7 under the “Class of Drugs” category in Schedule K of the Drugs Rules, 1945.
Schedule K specifies categories of drugs that are exempt from certain provisions related to the manufacture, sale and distribution of medicines under the Drugs and Cosmetics Act and Rules, subject to prescribed conditions. With the latest amendment, syrup-based medicines will no longer enjoy those exemptions and will require stricter compliance with regulatory provisions.
The move follows a draft notification issued by the government in December 2025 inviting objections and suggestions from stakeholders. The ministry stated that all representations received from the public were duly considered before finalising the amendment.
The decision was taken after consultation with the Drugs Technical Advisory Board (DTAB), the country’s highest statutory body dealing with technical matters related to pharmaceuticals and drug regulation.
Officials said the amendment comes amid heightened global scrutiny of cough syrups and other liquid oral formulations following reports of contamination-linked child deaths in several countries over the past few years.
According to sources, the new regulatory framework is expected to improve traceability, accountability and quality control across the pharmaceutical supply chain by ensuring that manufacturers, distributors and sellers adhere to stricter licensing and monitoring requirements.
The government believes that the measure will strengthen safeguards against the misuse of syrup-based medicines and enhance overall patient safety while ensuring better regulatory supervision of such products across the country.
